The Oncology Institute, Inc. (NASDAQ:TOI) CEO Acquires $23,545.60 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) CEO Daniel Virnich bought 22,640 shares of the business's stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $1.04 per share, for a total transaction of $23,545.60. Following the purchase, the chief executive officer now owns 724,363 shares in the company, valued at approximately $753,337.52. This trade represents a 3.23 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Oncology Institute Stock Up 10.5 %

NASDAQ TOI traded up $0.12 during trading hours on Tuesday, hitting $1.26. The company had a trading volume of 1,194,217 shares, compared to its average volume of 706,440. The firm's 50 day moving average is $0.88 and its 200 day moving average is $0.49. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The Oncology Institute, Inc. has a fifty-two week low of $0.13 and a fifty-two week high of $1.63. The company has a market capitalization of $95.20 million, a price-to-earnings ratio of -1.62 and a beta of 0.41.

Oncology Institute (NASDAQ:TOI - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.06). The company had revenue of $100.27 million during the quarter, compared to analyst estimates of $109.15 million. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%.

Remove Ads

Institutional Trading of Oncology Institute

Several large investors have recently bought and sold shares of TOI. HighTower Advisors LLC boosted its stake in shares of Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company's stock valued at $27,000 after purchasing an additional 53,382 shares during the period. FreeGulliver LLC lifted its holdings in Oncology Institute by 219.3% in the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock worth $186,000 after buying an additional 412,578 shares in the last quarter. Tiff Advisory Services LLC lifted its holdings in Oncology Institute by 13.2% in the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after buying an additional 346,256 shares in the last quarter. Jane Street Group LLC boosted its position in Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock valued at $39,000 after buying an additional 109,769 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after acquiring an additional 12,000 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company's stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.